Erica J. Rogers - 02 Mar 2021 Form 4 Insider Report for Silk Road Medical Inc

Role: President and CEO, Director
Signature: /s/Mhairi Jones, by power of attorney
Issuer symbol: N/A
Transactions as of: 02 Mar 2021
Net transactions value: -$93,478
Form type: 4
Filing time: 29 Sep 2023, 18:00:00 UTC
Next filing: 12 May 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SILK	Common Stock	Sale	$93,478	-1,651	-0.61%	$56.62	267,988	02 Mar 2021	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on September 11, 2020, prior to the effectiveness of the revised requirements of Rule 10b5-1(c). In compliance with SEC guidance, the Reporting Person has not checked the box above but states that the Rule 10b5-1 trading plan is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
F2	This transaction was executed in multiple trades at price ranging from $56.55 to $56.70. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Content

The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on September 11, 2020, prior to the effectiveness of the revised requirements of Rule 10b5-1(c). In compliance with SEC guidance, the Reporting Person has not checked the box above but states that the Rule 10b5-1 trading plan is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

This transaction was executed in multiple trades at price ranging from $56.55 to $56.70. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.